ReviewFrontiers in immunology2022
Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 19 citations in OpenAlex.
- Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review.Human vaccines & immunotherapeutics · 2026Review
- Immune-related nephritis, ureteritis and cystitis secondary to immune checkpoint inhibitors: A case report and review of the literature.Experimental and therapeutic medicine · 2026Article
- When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Immune-Related Cystitis Following Immune Checkpoint Inhibitor Therapy: A Report of Two Cases.Case reports in medicine · 2026Article
- Bladder metastasis from gastric cancer presenting as acute post-renal obstruction during immunotherapy: a case report.Frontiers in oncology · 2026Article
- PD-1/PD-L1 inhibitor-related cystitis: clinical features, diagnostic exclusion, and outcomes in one definite and seven probable cases with an updated literature review.Frontiers in oncology · 2026Article
- Mycophenolate mofetil for corticosteroid-resistant immune-related cystitis associated with tislelizumab: a case report.Frontiers in immunology · 2026Article
- Immunotherapy-related cystitis induced by nivolumab: A case report and review of the literature.Urology case reports · 2025Article
- Clinical presentation of PD-1/PD-L1 immune checkpoint inhibitors induced cystitis.Investigational new drugs · 2025Article
- Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014-2024.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- The differentiation and intervention strategies for acute kidney injury after or induced by immune checkpoint inhibitors.American journal of cancer research · 2025Review
- Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system.Frontiers in immunology · 2025Article
- Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial.Therapeutic advances in medical oncology · 2025Article
- A Case of Isolated Autoimmune Ureteritis in A 25-Year-Old Male.European journal of case reports in internal medicine · 2025Article
- Novel Antimicrobial Approaches to Combat Bacterial Biofilms Associated with Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature.Frontiers in immunology · 2024Review
- Case reports of immune-related cystitis and the antibody combination hypothesis.Immunotherapy · 2024Article
- Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management.Pharmaceutical medicine · 2024Review
- [Immune Checkpoint Inhibitors Related Cystoureteritis: A Case Report and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) and anti-programmed death cell protein 1 (anti-PD-1), are increasingly prescribed in metastatic carcinoma therapy. ICI-related kidney injury is gradually recognized by clinicians. However, immune-related ureteritis and cystitis easily go undiagnosed. We report three cases of PD-1 monoclonal antibody (mAb)-related ureteritis and cystitis. We further carried out a review of the literature about ICI-related ureteritis and cystitis. The cases in our reports manifest urinary irritation, sterile pyuria, gross hematuria, hydronephrosis, dilation of the ureters, and acute kidney injury. Urinary irritation improved effectively; urinalysis and renal function returned to normal after glucocorticoid therapy. During ICI therapy, urinalysis and renal function and urinary imaging examination are recommended to be monitored regularly. It contributes to identify immune-related ureteritis/cystitis earlier to efficiently alleviate urinary symptoms and immunologic urinary tract injury through glucocorticoid therapy while avoiding the abuse of antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.